105 related articles for article (PubMed ID: 27803295)
1. Strong antineoplastic effects of metformin in preclinical models of liver carcinogenesis.
Cauchy F; Mebarki M; Leporq B; Laouirem S; Albuquerque M; Lambert S; Bourgoin P; Soubrane O; Van Beers BE; Faivre S; Bedossa P; Paradis V
Clin Sci (Lond); 2017 Jan; 131(1):27-36. PubMed ID: 27803295
[TBL] [Abstract][Full Text] [Related]
2. Metformin suppresses hepatocellular carcinoma cell growth through induction of cell cycle G1/G0 phase arrest and p21CIP and p27KIP expression and downregulation of cyclin D1 in vitro and in vivo.
Cai X; Hu X; Cai B; Wang Q; Li Y; Tan X; Hu H; Chen X; Huang J; Cheng J; Jing X
Oncol Rep; 2013 Nov; 30(5):2449-57. PubMed ID: 24008375
[TBL] [Abstract][Full Text] [Related]
3. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T
J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma.
Zheng L; Yang W; Wu F; Wang C; Yu L; Tang L; Qiu B; Li Y; Guo L; Wu M; Feng G; Zou D; Wang H
Clin Cancer Res; 2013 Oct; 19(19):5372-80. PubMed ID: 23942093
[TBL] [Abstract][Full Text] [Related]
5. Effect of the anti-diabetic drug metformin in hepatocellular carcinoma in vitro and in vivo.
Miyoshi H; Kato K; Iwama H; Maeda E; Sakamoto T; Fujita K; Toyota Y; Tani J; Nomura T; Mimura S; Kobayashi M; Morishita A; Kobara H; Mori H; Yoneyama H; Deguchi A; Himoto T; Kurokohchi K; Okano K; Suzuki Y; Murao K; Masaki T
Int J Oncol; 2014 Jul; 45(1):322-32. PubMed ID: 24806290
[TBL] [Abstract][Full Text] [Related]
6. Metformin Reduces Prostate Tumor Growth, in a Diet-Dependent Manner, by Modulating Multiple Signaling Pathways.
Sarmento-Cabral A; L-López F; Gahete MD; Castaño JP; Luque RM
Mol Cancer Res; 2017 Jul; 15(7):862-874. PubMed ID: 28385910
[TBL] [Abstract][Full Text] [Related]
7. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.
Chen X; Wang Y; Tao J; Shi Y; Gai X; Huang F; Ma Q; Zhou Z; Chen H; Zhang H; Liu Z; Sun Q; Peng H; Chen R; Jing Y; Yang H; Mao Y; Zhang H
Gastroenterology; 2015 Sep; 149(3):741-52.e14. PubMed ID: 25980751
[TBL] [Abstract][Full Text] [Related]
8. Metformin incombination with curcumin inhibits the growth, metastasis, and angiogenesis of hepatocellular carcinoma in vitro and in vivo.
Zhang HH; Zhang Y; Cheng YN; Gong FL; Cao ZQ; Yu LG; Guo XL
Mol Carcinog; 2018 Jan; 57(1):44-56. PubMed ID: 28833603
[TBL] [Abstract][Full Text] [Related]
9. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.
Zhang DM; Liu JS; Deng LJ; Chen MF; Yiu A; Cao HH; Tian HY; Fung KP; Kurihara H; Pan JX; Ye WC
Carcinogenesis; 2013 Jun; 34(6):1331-42. PubMed ID: 23393227
[TBL] [Abstract][Full Text] [Related]
10. Metformin decreases IL-22 secretion to suppress tumor growth in an orthotopic mouse model of hepatocellular carcinoma.
Zhao D; Long XD; Lu TF; Wang T; Zhang WW; Liu YX; Cui XL; Dai HJ; Xue F; Xia Q
Int J Cancer; 2015 Jun; 136(11):2556-65. PubMed ID: 25370454
[TBL] [Abstract][Full Text] [Related]
11. Combination of metformin and sorafenib suppresses proliferation and induces autophagy of hepatocellular carcinoma via targeting the mTOR pathway.
Ling S; Song L; Fan N; Feng T; Liu L; Yang X; Wang M; Li Y; Tian Y; Zhao F; Liu Y; Huang Q; Hou Z; Xu F; Shi L; Li Y
Int J Oncol; 2017 Jan; 50(1):297-309. PubMed ID: 27959383
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
Bagi CM; Gebhard DF; Andresen CJ
Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
[TBL] [Abstract][Full Text] [Related]
13. Sirolimus and metformin synergistically inhibit hepatocellular carcinoma cell proliferation and improve long-term survival in patients with HCC related to hepatitis B virus induced cirrhosis after liver transplantation.
Shen C; Peng C; Shen B; Zhu Z; Xu N; Li T; Xie J
Oncotarget; 2016 Sep; 7(38):62647-62656. PubMed ID: 27577068
[TBL] [Abstract][Full Text] [Related]
14. Metformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma cells.
Saito T; Chiba T; Yuki K; Zen Y; Oshima M; Koide S; Motoyama T; Ogasawara S; Suzuki E; Ooka Y; Tawada A; Tada M; Kanai F; Takiguchi Y; Iwama A; Yokosuka O
PLoS One; 2013; 8(7):e70010. PubMed ID: 23922888
[TBL] [Abstract][Full Text] [Related]
15. Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models.
Zi FM; He JS; Li Y; Wu C; Yang L; Yang Y; Wang LJ; He DH; Zhao Y; Wu WJ; Zheng GF; Han XY; Huang H; Yi Q; Cai Z
Cancer Lett; 2015 Jan; 356(2 Pt B):443-53. PubMed ID: 25305450
[TBL] [Abstract][Full Text] [Related]
16. Metformin in combination with 5-fluorouracil suppresses tumor growth by inhibiting the Warburg effect in human oral squamous cell carcinoma.
Harada K; Ferdous T; Harada T; Ueyama Y
Int J Oncol; 2016 Jul; 49(1):276-84. PubMed ID: 27210058
[TBL] [Abstract][Full Text] [Related]
17. Nitidine chloride inhibits hepatocellular carcinoma cell growth in vivo through the suppression of the JAK1/STAT3 signaling pathway.
Liao J; Xu T; Zheng JX; Lin JM; Cai QY; Yu DB; Peng J
Int J Mol Med; 2013 Jul; 32(1):79-84. PubMed ID: 23613111
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma.
Chan SL; Wong CH; Lau CP; Zhou Q; Hui CW; Lui VW; Ma BB; Chan AT; Yeo W
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1417-25. PubMed ID: 23546591
[TBL] [Abstract][Full Text] [Related]
19. High efficacy of intravesical treatment of metformin on bladder cancer in preclinical model.
Peng M; Su Q; Zeng Q; Li L; Liu Z; Xue L; Cheng Y; Huang Y; Tao T; Lv H; Li X; Tao X; Guo P; Chen AF; Yang X
Oncotarget; 2016 Feb; 7(8):9102-17. PubMed ID: 26802022
[TBL] [Abstract][Full Text] [Related]
20. MEK-ERK inhibition potentiates WAY-600-induced anti-cancer efficiency in preclinical hepatocellular carcinoma (HCC) models.
Wang K; Fan Y; Chen G; Wang Z; Kong D; Zhang P
Biochem Biophys Res Commun; 2016 May; 474(2):330-337. PubMed ID: 27107695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
